Correspondence 0001193125-26-174064 from Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc.
Date: April 23, 2026 · CIK: 0001636651 · Accession: 0001193125-26-174064
AI Filing Summary & Sentiment
Reasoning
Letter
OVID THERAPEUTICS INC.
441 Ninth Avenue, 14th Floor
New York, New York 10001
April 23, 2026
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Ms. Lauren Hamill
Re:
Ovid Therapeutics Inc.
Registration Statement on Form S-3 (File No. 333- 295218)
Request for Acceleration of Effective Date
Ms. Hamill:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333- 295218) (the “Registration Statement”) to become effective on April 24, 2026 at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please confirm that event with Jaime L. Chase of Cooley LLP at (202) 728-7096 or Laura Berezin of Cooley LLP at (650) 843-5128.
Very truly yours,
Ovid Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP OVID THERAPEUTICS INC. 441 Ninth Avenue, 14th Floor New York, New York 10001 April 23, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Lauren Hamill Re: Ovid Therapeutics Inc. Registration Statement on Form S-3 (File No. 333- 295218) Request for Acceleration of Effective Date Ms. Hamill: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333- 295218) (the “Registration Statement”) to become effective on April 24, 2026 at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. Once the Registration Statement has been declared effective, please confirm that event with Jaime L. Chase of Cooley LLP at (202) 728-7096 or Laura Berezin of Cooley LLP at (650) 843-5128. Very truly yours, Ovid Therapeutics Inc. By: /s/ Jeff Rona Jeff Rona Chief Business and Chief Financial Officer cc: Jeff Rona, Ovid Therapeutics Inc. Laura Berezin, Cooley LLP Jaime L. Chase, Cooley LLP